Pharmaron Beijing Co., Ltd. (3759.HK)

HKD 14.46

(7.11%)

Operating Income Summary of Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd.'s latest annual operating income in 2023 was 1.84 Billion CNY , up 9.35% from previous year.
Pharmaron Beijing Co., Ltd.'s latest quarterly operating income in 2024 Q2 was 960.82 Million CNY , up 257.96% from previous quarter.
Pharmaron Beijing Co., Ltd. reported an annual operating income of 1.68 Billion CNY in 2022, down -11.72% from previous year.
Pharmaron Beijing Co., Ltd. reported an annual operating income of 1.91 Billion CNY in 2021, up 44.61% from previous year.
Pharmaron Beijing Co., Ltd. reported a quarterly operating income of 268.41 Million CNY for 2024 Q1, down -48.32% from previous quarter.
Pharmaron Beijing Co., Ltd. reported a quarterly operating income of 397.99 Million CNY for 2024 Q3, down -58.58% from previous quarter.

Annual Operating Income Chart of Pharmaron Beijing Co., Ltd. (2023 - 2014)

Historical Annual Operating Income of Pharmaron Beijing Co., Ltd. (2023 - 2014)

Year	Operating Income	Operating Income Growth
2023	1.84 Billion CNY	9.35%
2022	1.68 Billion CNY	-11.72%
2021	1.91 Billion CNY	44.61%
2020	1.32 Billion CNY	109.64%
2019	631.48 Million CNY	66.16%
2018	380.04 Million CNY	44.52%
2017	262.96 Million CNY	38.52%
2016	189.83 Million CNY	160.36%
2015	72.91 Million CNY	196.21%
2014	24.61 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	960.82 Million CNY	257.96%
2024 Q1	268.41 Million CNY	-48.32%
2024 Q3	397.99 Million CNY	-58.58%
2023 Q1	431.57 Million CNY	-7.56%
2023 FY	1.84 Billion CNY	9.35%
2023 Q4	519.4 Million CNY	25.28%
2023 Q3	414.6 Million CNY	-14.04%
2023 Q2	482.3 Million CNY	11.76%
2022 Q1	320.06 Million CNY	-54.81%
2022 FY	1.68 Billion CNY	-11.72%
2022 Q4	466.88 Million CNY	25.03%
2022 Q3	373.41 Million CNY	-12.93%
2022 Q2	428.87 Million CNY	34.0%
2021 FY	1.91 Billion CNY	44.61%
2021 Q4	708.31 Million CNY	32.06%
2021 Q3	536.34 Million CNY	38.74%
2021 Q1	283.09 Million CNY	-33.56%
2021 Q2	386.58 Million CNY	36.56%
2020 Q2	417.69 Million CNY	251.31%
2020 Q1	118.89 Million CNY	-54.91%
2020 Q3	361.18 Million CNY	-13.53%
2020 FY	1.32 Billion CNY	109.64%
2020 Q4	426.06 Million CNY	17.96%
2019 Q1	61.69 Million CNY	-45.05%
2019 FY	631.48 Million CNY	66.16%
2019 Q4	263.66 Million CNY	42.35%
2019 Q3	185.22 Million CNY	53.21%
2019 Q2	120.89 Million CNY	95.96%
2018 Q1	46.79 Million CNY	-45.51%
2018 FY	380.04 Million CNY	44.52%
2018 Q4	112.28 Million CNY	-9.74%
2018 Q3	124.4 Million CNY	29.43%
2018 Q2	96.11 Million CNY	105.39%
2017 Q4	85.88 Million CNY	0.0%
2017 FY	262.96 Million CNY	38.52%
2016 FY	189.83 Million CNY	160.36%
2015 FY	72.91 Million CNY	196.21%
2014 FY	24.61 Million CNY	0.0%

Peer Operating Income Comparison of Pharmaron Beijing Co., Ltd.

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	-2626.791%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	-105.789%